Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Binimetinib, binimetinib
MEK162+ RAF265 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MEK162 + RAF265 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MEK162 + RAF265 | DRUG | - |
Inclusion Criteria: Patients with histologically or cytologically confirmed and non-resectable advanced solid tumors for which no further effective standard therapy exists. * The patients' tumors must contain documented activating somatic BRAFV600E\* , NRAS or KRAS mutations (except for pancreatic...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Binimetinib is an investigational small molecule kinase inhibitor being studied in oncology. It is being evaluated for epithelial ovarian cancer, advanced solid tumors, metastatic colorectal cancer, advanced KRAS positive metastatic colorectal cancer, BRAF or NRAS mutant metastatic melanoma, and melanoma stage III. It is currently in Phase 2 clinical development.
Binimetinib is a kinase inhibitor, belonging to the -tinib class of drugs. It targets MEK, a kinase in the RAS/RAF/MEK/ERK pathway. By inhibiting MEK, it is designed to block signaling that drives tumor growth in cancers with RAS or BRAF mutations.
Binimetinib is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 2 clinical trials for multiple oncology indications.
Binimetinib is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. It is being studied across multiple oncology indications, including advanced solid tumors and metastatic colorectal cancer.
Binimetinib has been studied in several clinical trials. NCT01352273 was a Phase 1 trial in advanced solid tumors with RAS or BRAFV600E mutations. NCT01649336 was a Phase 1 trial in ovarian, fallopian tube, or peritoneal cancer. NCT01763164 was a Phase 3 trial in NRAS-mutant melanoma. NCT03271047 is a Phase 2 trial in MSS, RAS-mutant colorectal cancer.
Yes, Binimetinib is also known as MEK162. Clinical trials such as NCT01352273 and NCT01649336 refer to the drug as MEK162. This alternative name is used in research settings and historical trial documentation.